Effects of selective serotonin reuptake inhibitors and other antidepressant drugs on the risk of hip fracture: a case-control study in an elderly Mediterranean population
| Autor: | Ferran Torres, Caridad Pontes, Roser Vives, Dolors Capella, Irene Lopez-Rico, Maria Queralt Gorgas |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Population Osteoporosis 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine medicine Humans 030212 general & internal medicine General Pharmacology Toxicology and Pharmaceutics Medical prescription education Aged Original Research Aged 80 and over education.field_of_study Sertraline Hip fracture business.industry Hip Fractures Medical record Middle Aged medicine.disease Antidepressive Agents Case-Control Studies Antidepressant Reuptake inhibitor business Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | Eur J Hosp Pharm |
| ISSN: | 2047-9956 |
| Popis: | Objectives To describe the association between exposure to different antidepressant drugs and hip fracture in an elderly Mediterranean population. Methods Cases were all patients aged 50–95 years admitted to the emergency room of our hospital with hip fracture not related to a high intensity trauma during 2010. For each case, four controls were identified from primary care electronic medical records matched by age (±3 years), gender, date of consultation at the primary care centre (±1 month) and primary care centre. Pharmacological treatments received within the previous 5 years were retrieved from the prescription records. Crude and adjusted risks associated with exposures were calculated by conditional logistic regression. ORs were adjusted by matching variables and by significant risk factors identified in the bivariate analysis (prescription of ≥4 drugs, osteoporosis, diabetes mellitus and previous fracture). Results 136 cases and 544 controls were analysed. Adjusted OR (95% CI) for hip fracture associated with exposure to any antidepressants was 2.42 (1.24 to 4.73); for selective serotonin reuptake inhibitors (SSRIs) it was 3.52 (1.67 to 7.41), for non-selective monoamine reuptake inhibitors 1.07 (0.18 to 6.46) and for other antidepressants 0.82 (0.27 to 2.48). Sertraline (OR 3.88 (1.15 to 13.09)) was the only active principle with significant adjusted risk. When only exposures >6 months were considered, significant risks persisted for SSRIs (OR 2.64 (1.10 to 6.37)). Conclusions The results of this study are coincident with other studies in which SSRIs, but not other types of antidepressants, are associated with an increased risk of hip fracture in our setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|